Dabigatran versus warfarin in patients with atrial fibrillation.

By S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, Janice Pogue, P. Reilly, E. Themeles, Jeanne Varrone and 10 more. New England Journal of Medicine, 2009

9,875 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Neurology

View Paper: https://www.semanticscholar.org/paper/427811a925a8fe072dd877084152c94cc7f7f553

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Stanley Nattel
2. Gerhard Hindricks
3. Robert M. Califf
4. Ulrich Schotten
5. Gregory Y. H. Lip
6. Joseph S. Alpert
7. A. Goette
8. Paulus Kirchhof

In Internal Medicine

1. Gregory Y. H. Lip
2. J. Halperin
3. Cynthia Rudin
4. Berk Ustun
5. Benjamin Letham

In Neurology

1. Richard C. Becker
2. Alejandro Rabinstein

Citations in the corpus

• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, methodology): “Based on these new developments, a novel classification has recently been suggested where a functional EHRA (Evaluated Heartvalves, Rheumatic or Artificial) categorization is proposed, depending on the type of OAC use in patients with AF.6 In this scheme, EHRA Type 1 refers to AF patients with VHD n”
• Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “Direct thrombin inhibitors (DTI) are used for primary stroke prevention in patients with non-valvular atrial fibrillation [152], for treatment of deep venous thrombosis and pulmonary embolus [153, 154], and in the management of heparin-induced thrombocytopenia [155].”
• Dabigatran versus warfarin in patients with mechanical heart valves. (2013, background): “Previous transient ischemic attack 4 (2) 3 (4)”